 Hydroxymethylglutaryl-CoA Reductase Inhibitors
"Hydroxymethylglutaryl-CoA Reductase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.
| Descriptor ID |
D019161
|
| MeSH Number(s) |
D27.505.519.186.071.202.370 D27.505.519.389.370 D27.505.954.557.500.202.370
|
| Concept/Terms |
Hydroxymethylglutaryl-CoA Reductase Inhibitors- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Hydroxymethylglutaryl CoA Reductase Inhibitors
- Inhibitors, Hydroxymethylglutaryl-CoA Reductase
- Reductase Inhibitors, Hydroxymethylglutaryl-CoA
- Statins, HMG-CoA
- HMG-CoA Statins
- Statins, HMG CoA
- Inhibitors, Hydroxymethylglutaryl-CoA
- Hydroxymethylglutaryl-CoA Inhibitors
- Inhibitors, Hydroxymethylglutaryl CoA
- Inhibitors, Hydroxymethylglutaryl-Coenzyme A
- Hydroxymethylglutaryl-Coenzyme A Inhibitors
- Inhibitors, Hydroxymethylglutaryl Coenzyme A
- HMG-CoA Reductase Inhibitors
- HMG CoA Reductase Inhibitors
- Reductase Inhibitors, HMG-CoA
- Inhibitors, HMG-CoA Reductase
- Inhibitors, HMG CoA Reductase
|
Below are MeSH descriptors whose meaning is more general than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
This graph shows the total number of publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in this website by year, and whether "Hydroxymethylglutaryl-CoA Reductase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1987 | 0 | 1 | 1 | | 1991 | 1 | 0 | 1 | | 1994 | 0 | 2 | 2 | | 1995 | 1 | 0 | 1 | | 1996 | 2 | 0 | 2 | | 1997 | 3 | 0 | 3 | | 1998 | 2 | 1 | 3 | | 1999 | 3 | 0 | 3 | | 2000 | 2 | 3 | 5 | | 2001 | 5 | 2 | 7 | | 2002 | 6 | 4 | 10 | | 2003 | 17 | 4 | 21 | | 2004 | 16 | 4 | 20 | | 2005 | 16 | 2 | 18 | | 2006 | 13 | 4 | 17 | | 2007 | 15 | 3 | 18 | | 2008 | 21 | 10 | 31 | | 2009 | 14 | 3 | 17 | | 2010 | 8 | 3 | 11 | | 2011 | 13 | 2 | 15 | | 2012 | 7 | 5 | 12 | | 2013 | 10 | 3 | 13 | | 2014 | 11 | 9 | 20 | | 2015 | 7 | 2 | 9 | | 2016 | 7 | 4 | 11 | | 2017 | 12 | 4 | 16 | | 2018 | 3 | 3 | 6 | | 2019 | 5 | 4 | 9 | | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in Profiles.
-
Phan BAP, Ma Y, Scherzer R, Deeks SG, Hsue PY. Association between statin use, atherosclerosis, and mortality in HIV-infected adults. PLoS One. 2020; 15(4):e0232636.
-
Payne JM, Hearps SJC, Walsh KS, Paltin I, Barton B, Ullrich NJ, Haebich KM, Coghill D, Gioia GA, Cantor A, Cutter G, Tonsgard JH, Viskochil D, Rey-Casserly C, Schorry EK, Ackerson JD, Klesse L, Fisher MJ, Gutmann DH, Rosser T, Packer RJ, Korf B, Acosta MT, North KN. Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1. Ann Clin Transl Neurol. 2019 12; 6(12):2555-2565.
-
Davidson M. The Battle of the HDL Subfractions. Cardiovasc Revasc Med. 2019 11; 20(11):943-944.
-
Gaudet D, Durst R, Lepor N, Bakker-Arkema R, Bisgaier C, Masson L, Golden L, Kastelein JJ, Hegele RA, Stein E. Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1). Am J Cardiol. 2019 12 15; 124(12):1876-1880.
-
Toth PP, Bays HE, Brown WV, Catapano AL, Davidson MH, Farnier M, Tomassini JE, Jensen E, Polis AB, Tershakovec AM. Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapy. J Clin Lipidol. 2019 Nov - Dec; 13(6):997-1007.e8.
-
de Havenon A, Prabhakaran S, Turan T, Gottesman R, Yeatts S, Rost N. Is There Equipoise Regarding the Optimal Medical Treatment of Patients with Asymptomatic White Matter Hyperintensities? J Stroke Cerebrovasc Dis. 2019 Nov; 28(11):104371.
-
Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Atherosclerosis. 2019 09; 288:85-93.
-
Goldstein LB. Reader response: Association of statin use with spontaneous intracerebral hemorrhage: A cohort study. Neurology. 2019 04 23; 92(17):821-822.
-
Dahl A, Cai N, Ko A, Laakso M, Pajukanta P, Flint J, Zaitlen N. Reverse GWAS: Using genetics to identify and model phenotypic subtypes. PLoS Genet. 2019 04; 15(4):e1008009.
-
Shenkar R, Peiper A, Pardo H, Moore T, Lightle R, Girard R, Hobson N, Polster SP, Koskimäki J, Zhang D, Lyne SB, Cao Y, Chaudagar K, Saadat L, Gallione C, Pytel P, Liao JK, Marchuk D, Awad IA. Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive Pdcd10/Ccm3 Disease. Stroke. 2019 03; 50(3):738-744.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|